The estimated Net Worth of Jillian B. Thomsen is at least $4.71 Million dollars as of 16 February 2023. Ms. Thomsen owns over 10,267 units of Nektar Therapeutics stock worth over $391,871 and over the last 16 years she sold NKTR stock worth over $2,405,884. In addition, she makes $1,916,080 as Senior Vice President - Finance and Chief Accounting Officer at Nektar Therapeutics.
Jillian has made over 43 trades of the Nektar Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently she sold 10,267 units of NKTR stock worth $30,801 on 16 February 2023.
The largest trade she's ever made was exercising 112,500 units of Nektar Therapeutics stock on 20 March 2017 worth over $1,120,500. On average, Jillian trades about 9,003 units every 45 days since 2008. As of 16 February 2023 she still owns at least 313,497 units of Nektar Therapeutics stock.
You can see the complete history of Ms. Thomsen stock trades at the bottom of the page.
Jillian B. Thomsen serves as Senior Vice President - Finance, Chief Accounting Officer of the Company. From March 2006 through March 2008, Ms. Thomsen served as our Vice President Finance and Corporate Controller and from April 2008 through January 2010 she served as our Vice President Finance and Chief Accounting Officer. Before joining Nektar, Ms. Thomsen was Vice President Finance and Deputy Corporate Controller of Calpine Corporation from September 2002 to February 2006. Ms. Thomsen began her career as a certified public accountant at Arthur Andersen LLP, where she worked from 1990 to 2002, and specialized in audits of multinational consumer products, life sciences, manufacturing and energy companies. Ms. Thomsen holds a Masters of Accountancy from the University of Denver and a B.A. in Business Economics from Colorado College.
As the Senior Vice President - Finance and Chief Accounting Officer of Nektar Therapeutics, the total compensation of Jillian Thomsen at Nektar Therapeutics is $1,916,080. There are 5 executives at Nektar Therapeutics getting paid more, with Jonathan Zalevsky having the highest compensation of $39,242,200.
Jillian Thomsen is 54, she's been the Senior Vice President - Finance and Chief Accounting Officer of Nektar Therapeutics since 2010. There are 11 older and 7 younger executives at Nektar Therapeutics. The oldest executive at Nektar Therapeutics is Dr. Brian L. Kotzin, 72, who is the Sr. VP of Clinical Devel. & Head of Immunology.
Jillian's mailing address filed with the SEC is C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158.
Over the last 21 years, insiders at Nektar Therapeutics have traded over $57,608,493 worth of Nektar Therapeutics stock and bought 90,000 units worth $1,628,550 . The most active insiders traders include Howard W Robin, Gil M Labrucherie, and John Nicholson. On average, Nektar Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $36,648. The most recent stock trade was executed by Jonathan Zalevsky on 19 August 2024, trading 6,866 units of NKTR stock currently worth $8,788.
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.
Nektar Therapeutics executives and other stock owners filed with the SEC include: